Bio-Rad Laboratories, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bio-Rad Laboratories, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 409.4 times by its yearly operating cash. Higher than almost all Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
2.7×Over the last 3 years its own operating cash covered its investment spending (capex) 2.7 times.
Higher than 78% of Healthcare companies in United States.
Cash Locked Ratio
$40For every $100 of sales, $40 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $37 tied up three years earlier.
More money tied up than 81% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
1/3 · 2/3Sales grew in 1 of the last 3 years; profit grew in 2 of 3.
Less steady than 51% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 8%
Sales fell 8% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-8% / -22%In 3 years sales changed by -8% while total assets changed by -22%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
409.4×Debt due within a year is covered 409.4 times by its yearly operating cash.
Higher than almost all Healthcare companies in United States.
Cash Cushion Ratio
+2%Cash, after subtracting all debt, equals 2% of its market value (net cash).
Lower than 65% of Healthcare companies in United States.
Tangible Assets Ratio
93%Of every $100 the company owns, $93 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 66% of Healthcare companies in United States.
Tangible Net Worth Ratio
90%Of every $100 of net worth, $90 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 72% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Bio-Rad Laboratories, Inc. owes $0.30 for every $1 it owns. Bio-Rad Laboratories, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
46.2Investors pay $46.2 for every $1 of Bio-Rad Laboratories, Inc.'s yearly profit, higher than 79% of Healthcare companies in United States.
P/B ratio
1.36The share price is 1.36 times Bio-Rad Laboratories, Inc.'s book value per share, lower than 70% of Healthcare companies in United States.
Market cap
$9.7 BThe total market value of all of Bio-Rad Laboratories, Inc.'s shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$7.2 BWhat Bio-Rad Laboratories, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$268.30Net worth divided by the number of shares. The share price of $364.15 is 1.4 times this, which is the P/B above.
Return on equity (ROE)
3.1%Bio-Rad Laboratories, Inc. earned 3.1% on its shareholders' money over the last year, higher than 78% of Healthcare companies in United States.
Owes vs Owns
0.30×Bio-Rad Laboratories, Inc. owes $0.30 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Dividend yield
NoneBio-Rad Laboratories, Inc. does not currently pay a dividend.
Revenue growth
+1%Revenue rose 1% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Profit growth
Back to profitBio-Rad Laboratories, Inc. returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
29.4%Bio-Rad Laboratories, Inc. keeps $29 of every $100 of revenue as net profit.
Cash quality
0.7×Cash from Bio-Rad Laboratories, Inc.'s business was 0.7× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
4.5×Bio-Rad Laboratories, Inc.'s operating profit covered its interest costs 4.5 times in the year to Dec 2025.
Cash vs debt
Net cashBio-Rad Laboratories, Inc. held $155 M more cash than debt (net cash) at Dec 2025.
Questions
What is Bio-Rad Laboratories, Inc.'s P/E ratio?
Investors pay $46.2 for every $1 of Bio-Rad Laboratories, Inc.'s yearly profit, higher than 79% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bio-Rad Laboratories, Inc.: $9.7 B ÷ $7.2 B (30 Jun 2026) = 1.4.
What is Bio-Rad Laboratories, Inc.'s return on equity?
Bio-Rad Laboratories, Inc. earned 3.1% on its shareholders' money over the last year, higher than 78% of Healthcare companies in United States.
How much does Bio-Rad Laboratories, Inc. owe compared with what it owns?
Bio-Rad Laboratories, Inc. owes $0.30 for every $1 it owns (low), lower than 60% of Healthcare companies in United States.
Does Bio-Rad Laboratories, Inc. pay a dividend?
No. Bio-Rad Laboratories, Inc. does not currently pay a dividend.
Is Bio-Rad Laboratories, Inc.'s revenue growing?
Revenue rose 1% in the year to Dec 2025, and shrank 3% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.